Pleuropericardial effusion is an extremely rare complication of gemcitabine chemotherapy. The patient was a 56-year-old woman administered systemic chemotherapy with gemcitabine for local recurrence of pancreatic cancer and lymph node metastasis developing 4 years after pancreaticoduodenectomy. Four months after the start of the chemotherapy, she presented with exertional dyspnea and edema in both her legs and face. Echocardiography and computed tomography revealed pericardial and bilateral pleural effusion. A pericardiocentesis was immediately performed to prevent the development of cardiac tamponade as well as to examine the cause of the pericardial effusion. As a result, the patient's exertional dyspnea and edema resolved. No metastases to the thorax or mediastinum were noted. A cytological study of the pericardial and pleural effusions revealed no malignant cells. Cultures for bacteria, mycobacteria and fungi were negative. Tests for autoantibodies indicating autoimmune disease were also negative, and hormonal assays for the detection of endocrine disease were normal. She was followed up after discontinuation of the gemcitabine treatment, and no further episodes of pericardial or pleural effusion occurred. Thus, it is speculated that the pericardial effusion and bilateral pleural effusion may have been caused by gemcitabine.
INTRODUCTION
Pleuropericardial effusion can develop in patients with acute pericarditis or acute pleuritis, or in association with a variety of systemic disorders including drug adverse effects. Procainamide (1, 2) , hydralazine (3, 4) , isoniazid (5, 6) and minoxidil (7) are well-known causative agents of pleuropericardial effusion. In addition, several reports have also described pleuropericardial effusion induced by anticancer drugs, such as dasatinib (8) , imatinib (9) and docetaxel (11) . However, drug-induced pleuropericardial effusion has seldom been reported with gemcitabine. Here, we report a patient who developed pleuropericardial effusion possibly caused by gemcitabine treatment. This is the first report of pleuropericardial effusion induced by treatment with gemcitabine alone.
CASE REPORT
The patient was a 56-year-old woman. Her past medical history included gastritis and insomnia, and she had been under treatment with ranitidine hydrochloride and alprazolam. She had no history of allergy. At the age of 51 years, she underwent a pancreaticoduodenectomy for the treatment of pancreatic cancer at another hospital. Gross examination of the resected specimen revealed a tumor (2 cm Â 1.5 cm Â 1.5 cm) arising from the head of the pancreas. Microscopic examination revealed a moderately differentiated tubular adenocarcinoma with lymphatic and venous invasion. The edge of the resected specimen was negative. A regional lymph node metastasis was found in 1 out of 38 dissected lymph nodes. She underwent a laparotomy based on a diagnosis of ileus 2 years after the pancreaticoduodenectomy. Since recovering from the ileus, she had been followed up without any further anticancer treatment. Four years after the pancreaticoduodenectomy, a laboratory examination revealed an elevation of her serum carbohydrate antigen 19-9 (CA19-9) level to 101.8 ng/ml and she was referred to our hospital for the first time. A computed tomographic (CT) examination of the abdomen performed at our hospital revealed a local recurrence (15 mm in diameter) and also two abdominal lymph node metastases. The patient was asymptomatic, and her ECOG performance status was 0 at the time of detection of the recurrence. A blood examination showed no abnormalities, except for mild elevation of the serum amylase level (199 IU/l) and the serum CA19-9 level (49 ng/ml). Systemic chemotherapy using gemcitabine was started for the treatment of the recurrence. During the first 4 months of treatment, the only adverse effects of gemcitabine were mild nausea and mild fatigue. Oral intake was sufficient. However, at 4 months after the start of the chemotherapy, she presented with complaints of exertional dyspnea and edema in both her legs and face. The edema steadily worsened over the course of the following 2 months. CT examinations revealed pericardial and bilateral pleural effusion, and she was admitted to our hospital with the diagnosis of pleuropericardial effusion. Upon admission, her blood pressure was 142/90 mmHg, pulse rate was 110 min 21 , regular, and body temperature was 37.68C. Her peripheral blood arterial oxygen saturation level was 94% under room air. Her ECOG performance status had worsened to 2 because of the exertional dyspnea. The first heart sound and second heart sound were distant; however, there was no audible murmur or pericardial friction rub. The breath sounds were normal vesicular, except for a decrease over the right lung areas, presumably on account of the pleural effusion. An electrocardiogram performed at admission revealed a sinus rhythm, low-voltage complexes and no ST elevations in any of the leads. Laboratory examination revealed slight anemia, proteinuria (2þ) and hematuria (3þ), which were not observed before the initiation of gemcitabine (Tables 1  and 2 ). The daily urinary protein excretion level was 1.92 g/ day. The serum creatinine level was of normal value throughout the entire course of this episode ( Table 1 ). The serum C-reactive protein level was 2.2 mg/dl. The thyroid hormone profile was normal. Complement-fixation tests were performed in paired serum specimens for antibodies against Coxsackie virus, adenovirus and echovirus, which are wellknown causes of pleuropericardial effusion. At the time of admission, the antibody titers for all of these viruses were 1:32 or less. A paired sample taken 4 weeks later showed a less than 4-fold increase in the titers when compared with the titers recorded at the time of admission (Table 3) . A rapid influenza diagnostic test yielded negative results for influenza A and B. Although the rheumatoid factor test was positive, the tests for other autoantibodies were normal ( Table 2 ). The possibility of collagen vascular disease was ruled out by a rheumatologist based on the absence of the characteristic arthralgia, skin sclerosis or antinuclear antibody in the serum. An X-ray of the chest revealed cardiac enlargement (CTR, 60%) and increased pulmonary markings. A chest CT revealed pericardial effusion and bilateral pleural effusion; no evidence of metastatic tumors was 846 GEM-induced pleuropericardial effusion observed (Figs 1 and 2 ). An emergency echocardiography demonstrated a large amount of pericardial effusion (left ventricle: 15 mm) and a slightly pendular left ventricular wall motion. The ejection fraction was 59%. An abdominal CT revealed local recurrence in the remnant stump of the pancreas; the tumor size was slightly decreased when compared with that before the start of gemcitabine therapy. The serum level of CA19-9 had decreased to 31 ng/ml. Pericardiocentesis was immediately performed to prevent the development complication of cardiac tamponade and to examine the cause of the pericardial effusion. An indwelling drain yielded 700 ml of fluid on the first day, which resulted in the improvement of the patient's hemodynamic condition and marked alleviation of both the exertional dyspnea and the edema; however, no evidence of decrease in the size of the bilateral pleural effusion was noted. Cytology of the pericardial and pleural fluid samples was negative for malignant cells, and both the pericardial and pleural fluid Figure 1 . Chest X-ray obtained upon admission shows cardiac enlargement (60%), increased pulmonary markings and bilateral pleural effusion. Cultures of both the pericardial and pleural fluid specimens for bacteria, mycobacteria and fungi were negative (Table 4) . To treat the residual bilateral pleural effusion, the patient was given furosemide 20 mg for 4 days and also a preparation of human serum albumin (8.8 g) for 3 days to counter the possible contribution of hypoalbuminemia, which may cause the pleuropericardial effusion to worsen. Thereafter, the bilateral pleural effusion completely resolved. The daily drainage volume of the pericardial effusion fluid decreased to ,100 ml on the 12th day after the pericardiocentesis procedure, and the drainage tube was removed. Echocardiography demonstrated the dramatic decrease in pericardial effusion (left ventricle: ,5 mm) and improvement of the ejection fraction to 76%. The patient was discharged from the hospital 20 days after the emergency admission. Two months later, an X-ray of the chest showed a normal cardiac shadow (Fig. 3) , and no evidence of pleural/ pericardial effusion. In view of the risk of relapse of the pleuropericardial effusions, re-administration of gemcitabine was avoided. Although we proposed other anticancer agents as second-line chemotherapy, she refused any additional anticancer treatment. Therefore, she received only supportive care thereafter and died 4 months later from hepatic metastasis and failure.
DISCUSSION
The main causes of pleuropericardial effusion are infection (viral, pyogenic, tuberculosis, fungal etc.), acute idiopathic, 848 GEM-induced pleuropericardial effusion uremia, neoplasia, myxedema, acute myocardial infarction, post-radiation reactions, drug-induced reactions, collagen vascular disease, inflammatory bowel disease, aortic dissection and trauma. In our case, a differential diagnosis between malignant effusion and a benign cause of the effusion was essential in view of the diagnosis of cancer recurrence. The fluid samples were found to be exudates, which by itself is not sufficient to rule out the possibility of malignant effusion. However, cytological examinations of the fluid samples revealed no malignant cells. Furthermore, although liver metastasis was diagnosed in our patient after she was discharged from our hospital, she did not have a relapse of the effusion for a long time after the removal of the drainage tube despite the absence of anticancer treatment. Therefore, a malignant effusion was thought to be unlikely. At the time of the diagnosis of pleuropericardial effusion, the patient's oral intake was sufficient and her serum albumin level was 3.5 g/dl. Therefore, hypoalbuminemia did not cause the pleuropericardial effusion. Although proteinuria (2þ) and hematuria (3þ) were observed at the time of the diagnosis of pleuropericardial effusion, the serum creatinine level was normal. The renal dysfunction may have been caused by hypertension and the chemotherapy. The severity of the renal dysfunction was too low to be a possible cause of the pleuropericardial effusion. Bacteriologic and mycobacteriologic cultures of the blood, pericardial and pleural fluid (both sides) samples were all negative. Complement fixation tests of paired serum samples to detect an elevation in the antibodies to major causative viruses of pleuropericardial effusion were negative. Chest pain, high fever and ST elevation on the electrocardiogram, which are typical findings of acute pericarditis induced by viral infection, were absent. The patient did not have any history of injury, radiation or thoracic surgery. Other causative diseases, such as collagen vascular diseases, cardiovascular diseases, renal failure and hypothyroidism, were excluded based on the results of the physical examination, laboratory examination and imaging studies. Although the use of common medicines was continued, with the discontinuation of gemcitabine, after the diagnosis of the pleuropericardial effusion, the effusion did not recur. In view of the above-mentioned clinical information, we concluded that the most probable cause of the pleuropericardial effusion in our patient was the gemcitabine treatment. Although the re-administration of gemcitabine with follow-up might have improved the reliability of our conclusion, such treatment was not ethically acceptable, especially as the patient refused any further chemotherapy.
Although pulmonary toxicity is a well-known side effect of gemcitabine, there have been only a few reports of pleural effusion developing as a complication secondary to the pulmonary toxicity of this drug (17 -20) . With regard to pericardial effusion, only one previous report describing four cases of pericardial effusion caused by gemcitabine-induced radiation recall reactions was identified (10) . Therefore, our case is the first report of pleuropericardial effusion induced by gemcitabine treatment alone.
The mechanism underlying the development of gemcitabine-induced pleuropericardial effusion is unknown. With regard to reports of pleuropericardial effusion caused by other anticancer agents, this has often been reported in patients treated with docetaxel, dasatinib or imatinib. Docetaxel is a cytotoxic agent that is toxic to the microtubule assembly in the cells. Docetaxel-induced pleuropericardial effusion is reported to be associated with systemic fluid retention caused by the capillary protein leak syndrome (11, 12) . Although no cases of pleuropericardial effusion have been reported, some cases of gemcitabine-induced systemic capillary leak syndrome have been reported previously (13 -15) . Favorable effects of corticosteroids, which significantly delay the onset of docetaxel-induced fluid retention, have been reported (16) , and this treatment could also be considered for the treatment of gemcitabine-induced pleuropericardial effusion. The colloid osmotic pressure of edema, the interstitial fluid pressure and the interstitial hydrostatic pressure were measured before and after treatment to explain the theory of treatment-induced capillary protein leakage as the mechanism responsible for the fluid retention in patients treated with docetaxel (12) . On the other hand, imatinib and dasatinib, molecular-targeted agents categorized as multitargeted tyrosine kinase inhibitors, have been reported to cause pleuropericardial effusion. The underlying mechanism is still unknown, but may involve an immune-mediated pathway or off-target inhibition of the platelet-derived growth factor receptor, b-polypeptide (8). Gemcitabine, a novel deoxycytidine analog antimetabolite, does not exert off-target kinase inhibition.
If the above-mentioned discussions are taken into consideration, the pleuropericardial effusion in our case could have been associated with the capillary leak syndrome induced by gemcitabine.
Complications of pleuropericardial effusion, especially cardiac tamponade, complicating pericardial effusion, and acute respiratory failure complicating pleural effusion are life-threatening and might have a rapid clinical course. Therefore, it should be kept in mind during chemotherapy with gemcitabine, especially when patients complain of dyspnea, tachycardia or edema.
CONCLUSION
We encountered a case of gemcitabine-induced pleuropericardial effusion in a patient with recurrent pancreatic cancer. Physicians should be aware of the possibility of gemcitabine-induced pleuropericardial effusion.
